<DOC>
	<DOCNO>NCT02819843</DOCNO>
	<brief_summary>The purpose phase II clinical study test good bad effect T-VEC ( talimogene laherparepvec ) without hypofractionated radiotherapy people melanoma , Merkel cell carcinoma , solid tumor skin metastasis .</brief_summary>
	<brief_title>A Study T-VEC ( Talimogene Laherparepvec ) With Without Radiotherapy Melanoma , Merkel Cell Carcinoma , Other Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<criteria>Man woman ≥ 18 year old Life expectancy &gt; 4 month Histopathologically confirm melanoma , Merkel cell carcinoma solid tumor malignancy Cutaneous subcutaneous soft tissue , superficial lymphatic metastasis suitable surgical resection Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Cutaneous subcutaneous soft tissue , superficial lymphatic metastasis amenable injection irradiation &gt; 10 mm long dimension ° Cutaneous metastasis region previous radiation therapy amenable radiation therapy part protocol least 6 month elapse since prior radiotherapy dose radiotherapy previously administer exceed equivalent dose 60 Gy 2 Gy equivalent fraction skin surface ( use linearquadratic modeling alpha/beta=11.5 ) Metastasis &gt; 10 mm long dimensionor exhibit radiotracer uptake consistent metastasis PET/CT Adequate coagulation function ( platelet count &gt; 50 k/mcL , international normalize ratio &lt; 1.5 ) Completion cancer therapy ( targeted therapy , chemotherapy , investigational therapy , immunotherapy , radiotherapy , surgery ) 14 day prior first dose protocol therapy For patient breast cancer : May continue ongoing antiestrogen therapy ( example , aromatase inhibitor ) May continue ongoing Her2 direct therapy ( example , trastuzumab ) Resolution stabilization clinically significant adverse event prior therapy ( complete least 14 day prior first dose TVEC ) Able provide valid write informed consent Active herpetic skin lesion prior complication HSV1 infection ( herpetic keratitis , herpetic encephalitis ) Receipt therapeutic anticoagulant Receipt live vaccine within 28 day plan first dose TVEC History symptomatic autoimmune disease ( lupus , scleroderma , Crohn 's disease , ulcerative colitis ) require systemic treatment ( example corticosteroid immunosuppressant ) ; replacement therapy ( example , thyroxine , insulin ) consider systemic treatment History high grade ( CTCAE ≥ Grade 3 ) immune mediate adverse event prior cancer immunotherapy History CTCAE ≥ Grade 2 immune mediate endocrinopathy prior cancer immunotherapy Intermittent chronic use oral intravenous antiherpetic drug ( acyclovir ) Serologic evidence prior hepatitis B C infection Previously infect , immune ( HBsAg negative/antiHBc positive/antiHBs positive ) Acutely infect ( HBsAg positive/antiHBc positive/antiHBc IgM positive/antiHBs negative ) Chronically infect ( HBsAg positive/antiHBc positive/antiHBc IgM negative/antiHBs negative ) Known human immunodeficiency virus ( HIV ) infection Known leukemia lymphoma Common variable immunodeficiency Patients require chronic high dose immunosuppressant include steroid ( prednisone daily equivalent ≥ 10 mg ) Known severe congenital acquire cellular humoral immunodeficient immunocompromised patient High likelihood protocol noncompliance ( opinion investigator ) Woman childbearing potential unwilling use effective contraception protocol treatment 3 month last dose Talimogene Laherparepvec Woman childbearing potential pregnant breastfeeding , plan become pregnant breastfeed protocol treatment 3 month last dose Talimogene Laherparepvec</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>T-VEC ( Talimogene Laherparepvec )</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>16-224</keyword>
</DOC>